These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 8573412)

  • 41. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
    Trovas GP; Lyritis GP; Galanos A; Raptou P; Constantelou E
    J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.
    Chesnut CH; McClung MR; Ensrud KE; Bell NH; Genant HK; Harris ST; Singer FR; Stock JL; Yood RA; Delmas PD
    Am J Med; 1995 Aug; 99(2):144-52. PubMed ID: 7625419
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
    Thamsborg G; Jensen JE; Kollerup G; Hauge EM; Melsen F; Sorensen OH
    Bone; 1996 Feb; 18(2):207-12. PubMed ID: 8833216
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
    Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
    Flicker L; Hopper JL; Larkins RG; Lichtenstein M; Buirski G; Wark JD
    Osteoporos Int; 1997; 7(1):29-35. PubMed ID: 9102059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An open-label extension study of alendronate treatment in elderly women with osteoporosis.
    Downs RW; Bone HG; McIlwain H; Baker MZ; Yates AJ; Lombardi A; Krupa D; Harning R
    Calcif Tissue Int; 1999 Jun; 64(6):463-9. PubMed ID: 10341016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate.
    Bianda T; Linka A; Junga G; Brunner H; Steinert H; Kiowski W; Schmid C
    Calcif Tissue Int; 2000 Aug; 67(2):116-21. PubMed ID: 10920215
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
    Wang SX; Li H
    Chin Med J (Engl); 2008 Jul; 121(14):1280-4. PubMed ID: 18713548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
    Rittmaster RS; Bolognese M; Ettinger MP; Hanley DA; Hodsman AB; Kendler DL; Rosen CJ
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis.
    Kollerup G; Hermann AP; Brixen K; Lindblad BE; Mosekilde L; Sørensen OH
    Calcif Tissue Int; 1994 Jan; 54(1):12-5. PubMed ID: 8118746
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.
    Plosker GL; McTavish D
    Drugs Aging; 1996 May; 8(5):378-400. PubMed ID: 8935399
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
    Chesnut CH; Silverman S; Andriano K; Genant H; Gimona A; Harris S; Kiel D; LeBoff M; Maricic M; Miller P; Moniz C; Peacock M; Richardson P; Watts N; Baylink D
    Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial.
    Felsenberg D; Alenfeld F; Bock O; Hammermeister C; Gowan W
    Maturitas; 1998 Nov; 31(1):35-44. PubMed ID: 10091203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
    Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ;
    N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nasal calcitonin for treatment of established osteoporosis.
    Overgaard K; Riis BJ; Christiansen C; Pødenphant J; Johansen JS
    Clin Endocrinol (Oxf); 1989 Apr; 30(4):435-42. PubMed ID: 2688995
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.
    Pols HA; Felsenberg D; Hanley DA; Stepán J; Muñoz-Torres M; Wilkin TJ; Qin-sheng G; Galich AM; Vandormael K; Yates AJ; Stych B
    Osteoporos Int; 1999; 9(5):461-8. PubMed ID: 10550467
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women.
    Bell NH; Bilezikian JP; Bone HG; Kaur A; Maragoto A; Santora AC;
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2792-7. PubMed ID: 12050252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.